此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

结核亚基重组疫苗GamTBvac的安全性和有效性研究

亚单位结核病疫苗 GamTBvac 在预防 18-45 岁志愿者发生与 HIV 感染无关的呼吸道结核病中的安全性和有效性的多中心、双盲、随机、安慰剂对照研究

这是一项多中心、双盲、随机(按 1:1 比例)安慰剂对照研究,旨在评估亚单位重组结核病疫苗 GamTBvac 对 18 岁志愿者发生与 HIV 感染无关的呼吸道结核病的安全性和保护效果-45 岁。

研究概览

地位

主动,不招人

条件

研究类型

介入性

注册 (估计的)

9500

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Saint Petersburg、俄罗斯、197706
        • City hospital #40

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人、年长者)

接受健康志愿者

是的

描述

纳入标准:

  1. 18-45岁(含)的男女志愿者;
  2. 来自结核病高发人群(每10万人30人以上)的志愿者;
  3. 没有活动性肺结核,通过胸部 X 光或计算机断层扫描证实;
  4. 体重指数18.5-30kg/m2(含)根据Quetelet的体重和身高指数;
  5. 根据现行法律签署参与研究的知情同意书;
  6. 根据病史或通过疤痕的存在确认的先前卡介苗 (BCG) 疫苗接种;
  7. 缺乏对分枝杆菌蛋白 ESAT6 和 CFP10 的免疫反应标志物,这表明在研究开始之前可能与结核分枝杆菌接触,并通过结核病皮肤试验证实;
  8. 在筛选时和首次接种疫苗当天,对具有保留生殖潜能的女性志愿者进行阴性妊娠试验;
  9. 保留生殖潜能的男性和女性参与者同意观察适当的避孕方法(双屏障方法:男用或女用避孕套和联合激素避孕药(可以使用口服、阴道和透皮形式)或在避孕期间使用带杀精子剂的避孕套或隔膜整个疫苗接种期间和疫苗接种完成后 1 个月例外:手术绝育(超过 6 个月)或绝经后(超过 12 个月);
  10. 男性参与者同意在整个疫苗接种期间和疫苗接种完成后1个月内不参加精子捐献。

非入选标准:

  1. 筛选时 HIV-1/2 抗体、HBsAg 或丙型肝炎抗体检测结果呈阳性;
  2. 肺外结核病史;
  3. 慢性非感染性呼吸道疾病史,包括特发性肺纤维化 (IPF)、支气管哮喘、慢性阻塞性肺病 (COPD) 或肺动脉高压。
  4. 筛查时有临床意义的心电图异常;
  5. 过敏史加重(支气管哮喘、过敏反应史);
  6. 对研究药物或安慰剂的任何成分过敏;药物不耐受史;
  7. 研究者认为可能会干扰疫苗安全性或有效性评估的任何疾病或药物摄入史或存在。
  8. 根据身体和实验室检查,任何可能的免疫缺陷状态的病史或存在;
  9. 自身免疫性疾病史(包括系统性红斑狼疮、1型糖尿病等);
  10. 在研究开始前不到 6 个月定期摄入(持续超过 2 周)免疫抑制剂或其他免疫调节药物(吸入或局部形式的皮质类固醇除外);
  11. 在研究开始前 3 个月内使用过免疫球蛋白或血液制品,或在研究期间按计划预约;
  12. 接种疫苗前 14 天内(口服)和接种疫苗前 28 天内(肠胃外)服用抗菌药物;
  13. 怀孕、哺乳、拒绝使用双重屏障避孕方法、妇女参与卵子捐赠计划;
  14. 志愿者无法理解目标、目标、研究设计,无法遵守规定的协议和访问时间表和程序;
  15. 参加本研究开始前不足3个月的药品临床试验,或计划参加另一项临床试验;
  16. 以前接受过 GamTBvac 疫苗和/或参与任何实验性抗结核疫苗的临床试验;
  17. 在本研究中第一次疫苗接种前不到一个月或在本研究中每次疫苗接种后一个月内进行的任何疫苗接种或计划疫苗接种。
  18. 关于酗酒、毒瘾、药物滥用的记忆信息;
  19. 麻醉药品和精神药品的尿液分析结果呈阳性;
  20. 乙醇测试​​呈阳性(呼出空气或使用唾液试纸)。

排除标准:

志愿者参与研究可能会因以下原因而终止:

  1. 呼吸系统原发性结核病的发展;
  2. 研究人员决定,为了志愿者本人的利益,该志愿者应该被排除在外;
  3. 志愿者有与研究疫苗相关的严重不良事件;
  4. 未能遵守参与研究的规则;
  5. 参赛者拒绝合作或不守纪律;
  6. 参与者被纳入违反了方案的纳入/非纳入标准;
  7. 任何其他重大不良事件的发展;
  8. 志愿者健康状况恶化。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Vaccine Group (Stage 1)
177 volunteers will be receiving GamTBvac. Subcutaneous administration of the vaccine will be performed at Vaccination Visits No. 1 and No. 3 (Day 1 and Day 57 ± 1) in an outpatient setting. After each vaccination, participants will be observed for 5 hours. Subsequent follow-up visits are planned as follows: Visit 2 (Day 7 ± 1), Visit 4 (Day 64 ± 1), Visit 5 (12 months ± 14 days), and Visit 6 (24 months ± 30 days).
亚基重组结核病疫苗 GamTBvac(用于制备皮下给药溶液的冻干物,5.35 毫克/剂量)
安慰剂比较:Placebo group (Stage 1)
177 volunteers will be receiving placebo. Subcutaneous administration of the placebo will be performed at Vaccination Visits No. 1 and No. 3 (Day 1 and Day 57 ± 1) in an outpatient setting. After each administration, participants will be observed for 5 hours. Subsequent follow-up visits are planned as follows: Visit 2 (Day 7 ± 1), Visit 4 (Day 64 ± 1), Visit 5 (12 months ± 14 days), and Visit 6 (24 months ± 30 days).
皮下给药安慰剂
实验性的:Vaccine Group (Stage 2)
1073 volunteers with a history of active pulmonary tuberculosis that resulted in cure without residual changes or with minor residual changes, without aggravating factors, and who at the time of participation are registered and under follow-up in Dispensary Group III will be receiving GamTBvac. Subcutaneous administration of GamTBvac will be performed at Vaccination Visits No. 1 and No. 3 (Day 1 and Day 57 ± 1) in an outpatient setting. Participants will be observed for 5 hours after each vaccination. Follow-up visits are planned as follows: Visit 2 (Day 7 ± 1), Visit 4 (Day 64 ± 1), Visit 5 (12 months ± 14 days), and Visit 6 (24 months ± 30 days). In addition, between Visit 5 and Visit 6, the investigator will contact participants by telephone once every 3 months (± 14 days) to assess their well-being and to record adverse events and concomitant therapy.
亚基重组结核病疫苗 GamTBvac(用于制备皮下给药溶液的冻干物,5.35 毫克/剂量)
安慰剂比较:Placebo group (Stage 2)
1073 volunteers with a history of active pulmonary tuberculosis that resulted in cure without residual changes or with minor residual changes, without aggravating factors, and who at the time of participation are registered and under follow-up in Dispensary Group III will be receiving placebo. Subcutaneous administration of placebo will be performed at Vaccination Visits No. 1 and No. 3 (Day 1 and Day 57 ± 1) in an outpatient setting. Participants will be observed for 5 hours after each administration. Follow-up visits are planned as follows: Visit 2 (Day 7 ± 1), Visit 4 (Day 64 ± 1), Visit 5 (12 months ± 14 days), and Visit 6 (24 months ± 30 days). In addition, between Visit 5 and Visit 6, the investigator will contact participants by telephone once every 3 months (± 14 days) to assess their well-being and to record adverse events and concomitant therapy.
皮下给药安慰剂
实验性的:Vaccine Group (Stage 3)
3500 volunteers with no history of active pulmonary tuberculosis will be receiving GamTBvac. Subcutaneous administration of the vaccine will be performed at Vaccination Visits No. 1 and No. 3 (Day 1 and Day 57 ± 1) in an outpatient setting. After each vaccination, participants will be observed for 5 hours. Subsequent follow-up visits are planned as follows: Visit 2 (Day 7 ± 1), Visit 4 (Day 64 ± 1), Visit 5 (12 months ± 14 days), and Visit 6 (24 months ± 30 days). In addition, between Visit 5 and Visit 6, the investigator will contact participants by telephone once every 3 months (± 14 days) to assess their well-being and to record adverse events and concomitant therapy.
亚基重组结核病疫苗 GamTBvac(用于制备皮下给药溶液的冻干物,5.35 毫克/剂量)
安慰剂比较:Placebo group (Stage 3)
3500 volunteers with no history of active pulmonary tuberculosis will be receiving placebo. Subcutaneous administration of the placebo will be performed at Vaccination Visits No. 1 and No. 3 (Day 1 and Day 57 ± 1) in an outpatient setting. After each administration, participants will be observed for 5 hours. Subsequent follow-up visits are planned as follows: Visit 2 (Day 7 ± 1), Visit 4 (Day 64 ± 1), Visit 5 (12 months ± 14 days), and Visit 6 (24 months ± 30 days). In addition, between Visit 5 and Visit 6, the investigator will contact participants by telephone once every 3 months (± 14 days) to assess their well-being and to record adverse events and concomitant therapy.
皮下给药安慰剂

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Efficacy assessment - Stage 1
大体时间:24 months after vaccination
Efficacy will be assessed in volunteers aged 18 years and older. All study participants will be informed of the potential signs and symptoms indicative of pulmonary tuberculosis and will be instructed to report to the study site promptly should any such symptoms develop, in order to undergo an Unscheduled Visit. For Stage 1, the primary efficacy endpoint will be the incidence rate of respiratory tuberculosis. The diagnosis will be confirmed by the presence of pulmonary foci or infiltrations (physiological parameter) as determined by chest radiography (diagnostic test).
24 months after vaccination
Primary endpoint for Stage 2 of the study
大体时间:24 months after vaccination
The prophylactic efficacy of the GamTBvac vaccine will be assessed by comparing the incidence rate of active pulmonary tuberculosis cases between the study groups during the post-vaccination follow-up period in volunteers with a prior history of active respiratory tuberculosis, at 24 month after the first vaccination.
24 months after vaccination
Primary endpoint for Stage 3 of the study
大体时间:24 months after vaccination
The prophylactic efficacy of the GamTBvac vaccine will be assessed by comparing the incidence rate of active pulmonary tuberculosis cases between the study groups during the post-vaccination follow-up period in volunteers with no prior history of active respiratory tuberculosis, at 24 months after the first vaccination.
24 months after vaccination
Safety Endpoint Analysis
大体时间:24 months after the vaccination
Safety analyses will be performed in the safety population (SAF). The number and percentage of volunteers with adverse events (AEs) and serious adverse events (SAEs) will be tabulated by system organ class (SOC) and preferred term (PT) according to the MedDRA dictionary, by relationship to the investigational product.
24 months after the vaccination

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年1月20日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2021年7月9日

首先提交符合 QC 标准的

2021年7月14日

首次发布 (实际的)

2021年7月23日

研究记录更新

最后更新发布 (实际的)

2026年7月6日

上次提交的符合 QC 标准的更新

2026年7月1日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • 02-GamTBvac-2020

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅